ASCO 2026 Wrap-Up: Seven Patient Takeaways from This Year's Conference

June 9, 2026 — a patient-focused synthesis of the ASCO 2026 Annual Meeting (June 5–9, Chicago), closing today.

The headline: The Plenary was about daraxonrasib — the pan-RAS inhibitor doubled overall survival (13.2 vs 6.7 months) in previously-treated metastatic KRAS-mutant pancreatic cancer (RASolute 302, LBA5). Beyond that, the meeting was a story of multiple Phase 3 readouts pushing previously-investigational drugs toward first-line and adjuvant standards: pan-RAS targeting reached Phase 3 in NSCLC and adjuvant PDAC at the same time, the PD-1/VEGF bispecific ivonescimab kept expanding its 1L footprint, T-DXd + pertuzumab (FDA-approved December 15, 2025 on DESTINY-Breast09) had its full dataset presented, tarlatamab moved from "second-line salvage in SCLC" toward "maintenance, frontline, and beyond SCLC," and the first personalized mRNA cancer vaccine in resected NSCLC continued recruitment in Phase 3.

This wrap-up follows our three pre-conference previews (NSCLC, ADCs, T-cell engagers) and pulls the seven threads most likely to change what patients hear in clinic over the next 12 months. Each takeaway names the trials that anchor the story, in the same biomarker-aware language we use across the rest of the site.

For each cited trial, we note whether it is currently recruiting in the ClinTrialFinder corpus (so you can search for sites near you) or whether it has already completed enrollment and led to an FDA approval. A short corpus-status table appears at the end of the post for transparency.

1. Pan-RAS targeting reaches prime time: daraxonrasib in NSCLC and adjuvant PDAC

The biggest mechanism-level story of ASCO 2026 was the maturation of RAS(ON) multi-selective inhibitors — drugs that target the active GTP-bound state of multiple RAS variants (G12D, G12V, G12C, G12R, Q61X), not just the G12C-only target of sotorasib and adagrasib. The lead compound is daraxonrasib (RMC-6236) from Revolution Medicines.

Two Phase 3 trials of daraxonrasib are now actively enrolling at the same time:

The Plenary headline: The pivotal RASolute 302 Phase 3 (NCT06625320, Active, not recruiting) was presented in the ASCO 2026 Plenary Session as Late-Breaking Abstract LBA5 by Brian Wolpin, MD MPH (Dana-Farber) on May 31. In previously-treated metastatic KRAS-mutant pancreatic adenocarcinoma, daraxonrasib delivered a median overall survival of 13.2 vs 6.7 months (HR 0.40, p<0.0001), with median PFS 7.2 vs 3.6 months and an objective response rate of 31.6% vs 11.2% — the largest OS improvement ever reported in 2L+ metastatic PDAC. The trial has completed enrollment and is the basis for an expected near-term FDA filing.

The adjuvant PDAC enrollment (RASolute 304) is the more striking forward-looking move. Roughly 90% of pancreatic adenocarcinomas carry a KRAS mutation (most commonly G12D, G12V, or G12R — not the G12C subset that sotorasib and adagrasib hit). Until daraxonrasib, the KRAS-targeted toolkit didn't reach most PDAC patients. A successful RASolute 304 readout would put a targeted therapy into the post-surgery PDAC pathway for the first time.

Two additional variant-selective companions from the same RAS(ON) franchise are in Phase 1 / 1b / 2 and were also discussed at the meeting:

Ask your oncologist (KRAS-mutant cancer):

See the daraxonrasib drug page for the full trial list.

2. Ivonescimab keeps stacking 1L Phase 3s — and moves into TNBC and biliary

Ivonescimab (AK112, the Akeso / Summit Therapeutics PD-1 × VEGF bispecific) was already a 1L NSCLC story going into the meeting after HARMONi-2 beat pembrolizumab on PFS in PD-L1-positive NSCLC in late 2024. ASCO 2026 confirmed how broadly the drug is being deployed:

The pattern is the same in every indication: ivonescimab is being tested directly against the current pembrolizumab-based standard, not added to it. Whether the next 12–18 months of readouts confirm the HARMONi-2 1L superiority signal will define whether US patients eventually have access to the drug as an alternative to pembrolizumab.

See the ivonescimab drug page for the full Phase 3 footprint across NSCLC, SCLC, breast, head and neck, colorectal, and other cancers.

3. T-DXd + pertuzumab is the new HER2-positive metastatic breast cancer 1L standard

The DESTINY-Breast09 readout (primary data presented as Late-Breaking Abstract LBA1008 at ASCO 2025; an exploratory treatment-duration follow-up was presented at ASCO 2026 as Rapid Oral Abstract #1021) is the practice-changing breast cancer story of the meeting. Trastuzumab deruxtecan (T-DXd, Enhertu) plus pertuzumab — vs the prior standard taxane + trastuzumab + pertuzumab (THP) — cut the risk of disease progression or death by 44%, with median PFS 40.7 months vs 26.9 months (HR 0.56, p<0.0001). The FDA approved this indication on December 15, 2025 based on this trial; ASCO 2026 added the exploratory analysis of treatment duration and outcomes by response category.

For patients newly diagnosed with HER2-positive metastatic breast cancer, this is the first new frontline standard in a decade. The trial that established it (DESTINY-Breast09, NCT04784715) has completed enrollment and is no longer accepting new patients — the drug is now available as standard care.

The broader T-DXd Phase 3 footprint continued to expand at the meeting, and the HER2-ADC class itself kept stacking pivotal trials:

See the T-DXd drug page for the full active-trial list.

Ask your oncologist (HER2+ or HER2-low cancer):

4. HER3-DXd reaches registrational Phase 3 in breast (HERTHENA-Breast04)

Patritumab deruxtecan (HER3-DXd, MK-1022, U3-1402) is the first HER3-targeted antibody-drug conjugate to reach Phase 3 in oncology. The HERTHENA-Breast04 registrational trial (NCT07060807, Phase 3, Daiichi Sankyo / Merck) is now actively recruiting in HR+/HER2-negative metastatic breast cancer. (The Phase 2 neoadjuvant TNBC / HR-low HER2-negative study NCT06797635 is the actual HERTHENA-Breast03 — the trial numbering is non-sequential by stage.)

What makes HER3-DXd notable for patients: HER3 (ErbB3) is broadly expressed across many tumor types — especially upregulated in EGFR-mutant NSCLC after osimertinib resistance — making it a wider target than HER2 alone. The active companion program at ASCO 2026 included:

If you have a HER3-expressing tumor — especially EGFR-mutant NSCLC after osimertinib progression, or HR-positive or triple-negative metastatic breast cancer past standard lines — HER3-DXd is now a real trial-stage option. See the patritumab deruxtecan drug page for the full active-trial list.

5. Tarlatamab matures: maintenance in SCLC, expansion into NEC and brain

Tarlatamab (Imdelltra, Amgen's DLL3 × CD3 BiTE) was already FDA full-approved for second-line ES-SCLC in November 2025 (based on the Phase 3 DeLLphi-304 trial). ASCO 2026 marked the transition from "this works as second-line" to "this works earlier, more conveniently, and in other DLL3-expressing cancers." Three threads matter for patients:

Maintenance + frontline in ES-SCLC

SubQ formulation and outpatient delivery

Beyond SCLC: extrapulmonary NEC and brain tumors

If you have a neuroendocrine cancer — pulmonary or extrapulmonary — ask about DLL3 immunohistochemistry on your tumor and which tarlatamab trial matches your line of therapy. See the tarlatamab drug page for the full trial list across SCLC, NEC, NEPC, MCC, and brain tumors.

6. PD-1/CTLA-4 and PD-1/TIGIT bispecifics keep expanding globally

Beyond ivonescimab (PD-1/VEGF), two other bispecific antibody mechanisms continued their global Phase 3 expansion at ASCO 2026:

Cadonilimab (PD-1/CTLA-4) — Akeso

Cadonilimab combines PD-1 inhibition (the established checkpoint) with CTLA-4 inhibition (the older ipilimumab target). It is the world's first approved PD-1/CTLA-4 bispecific antibody, with Chinese NMPA approval first granted in June 2022 for relapsed/metastatic cervical cancer (monotherapy) and later expanded to 1L gastric / gastroesophageal junction adenocarcinoma in combination with chemotherapy. It is not currently FDA-approved. Notable ASCO 2026 footprint includes:

See the cadonilimab drug page for the full footprint across gastric, cervical, hepatocellular, and other cancers.

Rilvegostomig (PD-1/TIGIT) — AstraZeneca

Rilvegostomig combines PD-1 with TIGIT (a different inhibitory receptor on T cells). AstraZeneca is enrolling it across multiple cancers:

See the rilvegostomig drug page for the full Phase 3 footprint.

Patient takeaway: if you have a cancer where pembrolizumab or durvalumab is the current standard, ask whether a bispecific-vs-checkpoint Phase 3 trial is open at a site near you. The trials almost always test the bispecific against the checkpoint — you're getting at least the current standard as the control arm.

7. The personalized mRNA cancer vaccine reaches Phase 3 in resected NSCLC

The Moderna / Merck individualized neoantigen mRNA cancer vaccine V940 (intismeran autogene) showed substantial recurrence-free survival benefit in adjuvant resected melanoma in 2023. ASCO 2026 highlighted the next step:

The reason this matters: each patient receives a custom-manufactured mRNA encoding approximately 34 neoantigens specific to their own resected tumor. It is not a one-size-fits-all vaccine. If positive, it would be the first personalized cancer vaccine approved as standard adjuvant care in NSCLC — and would set the template for similar trials in other resected solid tumors.

Ask your oncologist (resected stage II–IIIB NSCLC):

What didn't make this wrap-up (and why)

The bottom line for patients

ASCO 2026 didn't deliver a single "drug X replaces drug Y" headline. What it delivered was a steady push of several previously-investigational mechanisms into Phase 3 across multiple cancers at once: pan-RAS, PD-1/VEGF bispecifics, PD-1/CTLA-4 and PD-1/TIGIT bispecifics, HER3-targeted ADCs, DLL3 BiTEs beyond SCLC, and personalized mRNA vaccines in adjuvant solid tumors.

For patients, the practical implication is the same one we've been writing about all year: the right question to ask your oncologist today is not "what is the standard for my cancer?" but "given my biomarkers and prior therapies, what Phase 3 trial best matches my profile?" Most of the trials cited above are testing the new drug against the current standard, not instead of nothing — meaning enrollment almost always preserves at least standard care as the control arm.

If you'd like a starting point on what matches your specific situation, our guided questionnaire walks through cancer type, stage, biomarkers, and prior treatments step by step — no medical-record uploads required.

Corpus status of trials cited above

For transparency, here is the recruiting-status check for every NCT cited in this post. The ClinTrialFinder corpus only indexes actively recruiting interventional trials, so "not in corpus" generally means the trial has completed enrollment (in several cases because the drug has been FDA-approved on its data).

Find a trial matched to your situation

Use ClinTrialFinder's guided questionnaire to find trials based on your cancer type, biomarkers, prior treatments, and line of therapy.

Find Matching Trials

Related Resources

ASCO 2026 NSCLC Preview ASCO 2026 ADC Preview ASCO 2026 T-Cell Engager Preview ASCO 2026 Pancreatic Preview ASCO 2026 Prostate Preview Daraxonrasib Drug Page Ivonescimab Drug Page Trastuzumab Deruxtecan Drug Page Patritumab Deruxtecan (HER3-DXd) Drug Page Tarlatamab Drug Page Cadonilimab Drug Page Rilvegostomig Drug Page

Methodology note: This wrap-up is built from the active Phase 3 trial landscape going into ASCO 2026 and the abstracts publicly available during the meeting. Every NCT cited above was checked against the ClinTrialFinder recruiting corpus on June 9, 2026 (see corpus-status section above for the audit). This blog is for information only and is not medical advice. Trial eligibility, recruitment status, and treatment details can change — verify directly with the trial sponsor or on ClinicalTrials.gov before acting on any information here. ClinTrialFinder is an AI-powered clinical trial search tool, not a healthcare provider.